Table 2

Items and procedures of the study at baseline and each follow-up

	0 month	6 months ±30 days	12 months ±30 days	18 months ±30 days	2 years ±30 days	3 years ±30 days	4 years ±30 days	5 years ±30 days
Informed consent	×	–	–	–	–	–	–	–
Inclusion/exclusion criteria	×	–	–	–	–	–	–	–
Physical examination	×	×	×	×	×	×	×	×
Anthropomorphic measures*	×	×	×	×	×	×	×	×
Blood cellular evaluation	×	×	×	×	×	×	×	×
Blood biochemical analysis	×	×	×	×	×	×	×	×
Serum electrolytes	×	×	×	×	×	×	×	×
Routine urine test	×	×	×	×	×	×	×	×
24-Hour urine protein	×	×	×	×	×	×	×	×
24-Hour urine electrolytes	×	–	×	–	×	×	×	×
Urinary albumin to creatinine ratio	×	×	×	×	×	×	×	×
Intact PTH	×	–	×	–	×	×	×	×
Cystatin C	×	×	×	×	×	×	×	×
hs-CRP	×	–	×	–	×	×	×	×
Electrocardiography	×	–	×	–	×	×	×	×
Carotid artery ultrasound	×	–	×	–	×	×	×	×
Echocardiogram	×	–	×	–	×	×	×	×
ABPM	×	–	×	–	×	×	×	×
BIA	×	–	×	–	×	×	×	×
Lateral abdominal radiograph	×	–	×	–	×	×	×	×
Demographic data and medical history	×	–	–	–	–	–	–	–
Sample collection	×	–	×	–	×	×	×	×
ADL	×	–	×	–	×	×	×	×
KDQOL-36	×	–	×	–	×	×	×	×
MIS	×	×	×	×	×	×	×	×
GDS-15	×	–	×	–	×	×	×	×
MoCA	×	–	–	–	–	–	–	×
Drug collected	×	×	×	×	×	×	×	×
Adverse events	×	×	×	×	×	×	×	×
Clinical outcomes	–	×	×	×	×	×	×	×

↵x, item that will be collected.
-, item that will not be collected.
*Anthropomorphic measures: height, weight, waist circumference, hip circumference, mid-arm circumference, triceps skinfold thickness, blood pressure, heart rate, handgrip strength and 5 m measured walk.
ABPM, ambulatory blood pressure monitoring; ADL, Activity of Daily Living scale; BIA, bioelectrical impedance analysis; GDS, Geriatric Depression Scale; hs-CRP, high-sensitivity C reactive protein; KDQOL-36, Kidney Disease Quality of Life-36; MIS, malnutrition inflammation score; MoCA, Montreal Cognitive Assessment; PTH, parathyroid hormone.